Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor,
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...
US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
Pfizer’s Talzenna-Xtandi combination has marked a major step forward in treating advanced prostate cancer, improving patient ...
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback